Theriva™ biologics reports third quarter 2023 operational highlights and financial results

- virage, the phase 2b clinical trial of vcn-01 in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma remains on track to complete enrollment in the first half of 2024; multiple patients have received second doses of vcn-01, which continues to be well tolerated with a safety profile consistent with prior clinical trials -
TOVX Ratings Summary
TOVX Quant Ranking